These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 10553041)

  • 1. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    Shimizu J; Yamazaki S; Sakaguchi S
    J Immunol; 1999 Nov; 163(10):5211-8. PubMed ID: 10553041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.
    Itoh M; Takahashi T; Sakaguchi N; Kuniyasu Y; Shimizu J; Otsuka F; Sakaguchi S
    J Immunol; 1999 May; 162(9):5317-26. PubMed ID: 10228007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    Sakaguchi S; Sakaguchi N; Asano M; Itoh M; Toda M
    J Immunol; 1995 Aug; 155(3):1151-64. PubMed ID: 7636184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
    Takahashi T; Kuniyasu Y; Toda M; Sakaguchi N; Itoh M; Iwata M; Shimizu J; Sakaguchi S
    Int Immunol; 1998 Dec; 10(12):1969-80. PubMed ID: 9885918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    Sutmuller RP; van Duivenvoorde LM; van Elsas A; Schumacher TN; Wildenberg ME; Allison JP; Toes RE; Offringa R; Melief CJ
    J Exp Med; 2001 Sep; 194(6):823-32. PubMed ID: 11560997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.
    Nishikawa H; Kato T; Tawara I; Ikeda H; Kuribayashi K; Allen PM; Schreiber RD; Old LJ; Shiku H
    J Immunol; 2005 Oct; 175(7):4433-40. PubMed ID: 16177085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific.
    Thornton AM; Shevach EM
    J Immunol; 2000 Jan; 164(1):183-90. PubMed ID: 10605010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.
    Casares N; Arribillaga L; Sarobe P; Dotor J; Lopez-Diaz de Cerio A; Melero I; Prieto J; Borrás-Cuesta F; Lasarte JJ
    J Immunol; 2003 Dec; 171(11):5931-9. PubMed ID: 14634104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease.
    McHugh RS; Shevach EM
    J Immunol; 2002 Jun; 168(12):5979-83. PubMed ID: 12055202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.
    Suri-Payer E; Amar AZ; Thornton AM; Shevach EM
    J Immunol; 1998 Feb; 160(3):1212-8. PubMed ID: 9570536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+CD25+ regulatory T cells generated in response to insulin B:9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells.
    Mukherjee R; Chaturvedi P; Qin HY; Singh B
    J Autoimmun; 2003 Nov; 21(3):221-37. PubMed ID: 14599847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells.
    Uraushihara K; Kanai T; Ko K; Totsuka T; Makita S; Iiyama R; Nakamura T; Watanabe M
    J Immunol; 2003 Jul; 171(2):708-16. PubMed ID: 12847237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    Tanaka H; Tanaka J; Kjaergaard J; Shu S
    J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells.
    Aseffa A; Gumy A; Launois P; MacDonald HR; Louis JA; Tacchini-Cottier F
    J Immunol; 2002 Sep; 169(6):3232-41. PubMed ID: 12218142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.
    Hara M; Kingsley CI; Niimi M; Read S; Turvey SE; Bushell AR; Morris PJ; Powrie F; Wood KJ
    J Immunol; 2001 Mar; 166(6):3789-96. PubMed ID: 11238621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses.
    Kingsley CI; Karim M; Bushell AR; Wood KJ
    J Immunol; 2002 Feb; 168(3):1080-6. PubMed ID: 11801641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide specificity of thymic selection of CD4+CD25+ T cells.
    Pacholczyk R; Kraj P; Ignatowicz L
    J Immunol; 2002 Jan; 168(2):613-20. PubMed ID: 11777953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.